Q4 2024 · 13F-HR
Commodore Capital LPholdings as filed
Filed 2025-02-14 · accession 0001831942-25-000002
$1.36B
Reported value
31
Positions
2024-12-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| N5749R100 | 2GH | MERUS N V | $162.9M | 11.9% | 3,874,182 | Common | SOLE |
| 92243G108 | PCVX | VAXCYTE INC | $133.0M | 9.75% | 1,625,000 | Common | SOLE |
| 670703107 | NUVL | NUVALENT INC | $126.9M | 9.30% | 1,621,600 | Common | SOLE |
| 98420N105 | XENE | XENON PHARMACEUTICALS INC | $107.4M | 7.87% | 2,740,000 | Common | SOLE |
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS INC | $94.6M | 6.93% | 4,205,000 | Common | SOLE |
| 92337R101 | VERA | VERA THERAPEUTICS INC | $82.8M | 6.07% | 1,958,600 | Common | SOLE |
| 834203309 | SLNO | SOLENO THERAPEUTICS INC | $68.5M | 5.02% | 1,525,000 | Common | SOLE |
| G01767105 | ALKS | ALKERMES PLC | $66.1M | 4.85% | 2,300,000 | Common | SOLE |
| 67080M103 | NRIX | NURIX THERAPEUTICS INC | $56.5M | 4.14% | 3,000,000 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $53.7M | 3.93% | 6,881,629 | Common | SOLE |
| 00773J202 | SYRE | SPYRE THERAPEUTICS INC | $46.3M | 3.39% | 1,988,084 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $46.0M | 3.37% | 2,400,000 | Common | SOLE |
| 80706P103 | SRRK | SCHOLAR ROCK HLDG CORP | $41.1M | 3.01% | 950,000 | Common | SOLE |
| 152309100 | CNTA | CENTESSA PHARMACEUTICALS PLC | $37.2M | 2.72% | 2,218,425 | Common | SOLE |
| N69605108 | PHVS | PHARVARIS N V | $36.6M | 2.69% | 1,911,433 | Common | SOLE |
| 60255C885 | BRD1EUR | MIND MEDICINE MINDMED INC | $30.0M | 2.20% | 4,308,425 | Common | SOLE |
| 687604108 | ORKA | ORUKA THERAPEUTICS INC | $27.5M | 2.02% | 1,419,714 | Common | SOLE |
| 14147L108 | CRDF | CARDIFF ONCOLOGY INC | $23.4M | 1.71% | 5,384,616 | Common | SOLE |
| 45719W205 | IKT | INHIBIKASE THERAPEUTICS INC | $19.3M | 1.41% | 5,925,000 | Common | SOLE |
| 64135M105 | NGNE | NEUROGENE INC | $18.3M | 1.34% | 800,000 | Common | SOLE |
| 10919W405 | DRUG | BRIGHT MINDS BIOSCIENCES INC | $18.0M | 1.32% | 500,000 | Common | SOLE |
| 68622P109 | ORIC | ORIC PHARMACEUTICALS INC | $16.1M | 1.18% | 2,000,000 | Common | SOLE |
| 03770N101 | APGE | APOGEE THERAPEUTICS INC | $13.1M | 0.96% | 290,000 | Common | SOLE |
| 00370M103 | ABVX | ABIVAX SA | $9.4M | 0.69% | 1,284,110 | Common | SOLE |
| G70077105 | PCSC | PERCEPTIVE CAP SOLUTIONS COR | $7.6M | 0.56% | 750,000 | Common | SOLE |
| G4444H101 | BBOT | HELIX ACQUISITION CORP II | $5.3M | 0.38% | 500,000 | Common | SOLE |
| 15102K100 | CELC | CELCUITY INC | $5.2M | 0.38% | 400,000 | Common | SOLE |
| 92840H400 | VTGN | VISTAGEN THERAPEUTICS INC | $4.6M | 0.34% | 1,575,000 | Common | SOLE |
| 05338F306 | AVTX | AVALO THERAPEUTICS INC | $3.6M | 0.26% | 483,000 | Common | SOLE |
| 88427A107 | — | THIRD HARMONIC BIO INC | $2.4M | 0.18% | 237,704 | Common | SOLE |
| 65487U108 | NKTX | NKARTA INC | $876,102 | 0.06% | 351,848 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.